Burt Zweigenhaft, PhD, D.Litt


Association for Value-Based Cancer Care

Burt Zweigenhaft is Founder, Association for Value-Based Cancer Care (AVBCC). AVBCC is the fastest growing national specialty organization dedicated to improving the care of cancer patients and their quality of life, by discussing, considering, and evaluating the value equation as it relates to new and existing cancer therapies. This organization was established to provide a network for payers and oncology healthcare professionals to interact and network in order to promote optimal care for patients and their families
Mr Zweigenhaft serves as Executive Director Enterprise Pharmacy, Trade Relations and Strategy
Cancer Treatment Centers America Global, Inc (CTCA). CTCA is a national, comprehensive cancer care network, with five hospitals around the country and a growing footprint of Outpatient Care Centers and other locations. Founded in 1988 on a personalized, patient-centered approach to cancer care, CTCA® is dedicated to tailoring a combination of cancer treatments to the needs of each individual patient. From advanced genomic testing to state-of-the-art technologies and evidence-informed supportive therapies that target cancer-related side effects, comprehensive services are delivered by a team of cancer experts, all under one roof.
Mr Zweigenhaft is Managing Partner, Upstream Partners, New York, NY, where his guidance has supported several key drug launch market strategies with industry leaders, such as Gilead, Janssen, Pfizer, Genentech, and emerging biotechnology incubators. He also serves as Senior Advisor to the shareholder group, Cancer Treatment Centers of America, and is Past President of the National Association of Specialty Pharmacy, representing the industry on national policy, specialty pharmacy education, and government relations based in Washington, DC.
Previously, Mr Zweigenhaft was the Founder and held offices as the Chief Executive Officer and Vice Chairman of Onco360 Oncology Pharmacy, South Plainfield, NJ. The Onco360 model provides the full continuum of oncology pharmacy service solutions to more than 3000 community- and hospital-based hematologists, oncologists, and cancer centers of excellence in coordination with managed care providers insuring more than 45 million people. Mr Zweigenhaft’s vision and leadership developed the industry standards for the best practice oncology pharmacy model by incorporating the strengths of board-certified oncology pharmacists and oncology patient advocates to support the prospective and concurrent patient-centered oncology medical home model.


200 Park Avenue, Suite 300 
Florham Park, NJ 07932





  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos


Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

© 2020 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.